Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Other Non-Current Liabilities (2016 - 2025)

Historic Other Non-Current Liabilities for Arrowhead Pharmaceuticals (ARWR) over the last 12 years, with Q4 2025 value amounting to $375.0 million.

  • Arrowhead Pharmaceuticals' Other Non-Current Liabilities rose 813.81% to $375.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $375.0 million, marking a year-over-year increase of 813.81%. This contributed to the annual value of $367.4 million for FY2025, which is 762.71% up from last year.
  • As of Q4 2025, Arrowhead Pharmaceuticals' Other Non-Current Liabilities stood at $375.0 million, which was up 813.81% from $367.4 million recorded in Q3 2025.
  • Arrowhead Pharmaceuticals' 5-year Other Non-Current Liabilities high stood at $375.0 million for Q4 2025, and its period low was $252.8 million during Q4 2022.
  • Its 4-year average for Other Non-Current Liabilities is $313.5 million, with a median of $336.0 million in 2024.
  • Per our database at Business Quant, Arrowhead Pharmaceuticals' Other Non-Current Liabilities skyrocketed by 2773.74% in 2024 and then surged by 720.86% in 2025.
  • Arrowhead Pharmaceuticals' Other Non-Current Liabilities (Quarter) stood at $252.8 million in 2022, then grew by 8.24% to $273.7 million in 2023, then rose by 26.7% to $346.8 million in 2024, then grew by 8.14% to $375.0 million in 2025.
  • Its last three reported values are $375.0 million in Q4 2025, $367.4 million for Q3 2025, and $360.3 million during Q2 2025.